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Abstract
Hypertrophic  cardiomyopathy  (HCM)  is  an  autosomal  dominant  inherited  genetic  disease 
characterized by compensatory pathological left ventricle (LV) hypertrophy due to sarcomere 
dysfunction. In an important proportion of patients with HCM, the site and extent of cardiac 
hypertrophy results in severe obstruction to LV outflow tract (LVOT), contributing to disabling 
symptoms and increasing the risk of sudden cardiac death (SCD). In patients with progressive 
and/or refractory symptoms despite optimal pharmacological treatment, invasive therapies that 
diminish or abolish LVOT obstruction relieve heart failure-related symptoms, improve quality 
of life and could be associated with long-term survival similar to that observed in the general 
population.  The  gold  standard  in  this  respect  is  surgical  septal  myectomy,  which  might  be 
supplementary  associated  with  a  reduction  in  SCD.  Percutaneous  techniques,  particularly 
alcohol  septal  ablation  (ASA)  and  more  recently  radiofrequency  (RF)  septal  ablation,  can 
achieve  LVOT gradient  reduction  and symptomatic  benefit  in  a large  proportion of HOCM 
patients at the cost of a supposedly limited septal myocardial  necrosis and a 10-20% risk of 
chronic atrioventricular block. After an initial period of enthusiasm, standard DDD pacing failed 
to show in randomized trials significant LVOT gradient reductions and objective improvement 
in exercise capacity. However, case reports and recent small pilot studies suggested that atrial 
synchronous  LV  or  biventricular  (biV)  pacing  significantly  reduce  LVOT  obstruction  and 
improve symptoms (acutely as well as long-term) in a large proportion of severely symptomatic 
HOCM patients not suitable to other gradient reduction therapies. Moreover, biV/LV pacing in 
HOCM seems to be associated with significant LV reverse remodelling. 
Keywords:  hypertrophic  obstructive  cardiomyopathy,  intraventricular  gradient,  biventricular 
pacing,  reverse  remodelling.                                         
Introduction
Hypertrophic  cardiomyopathy  (HCM)  is  an  autosomal  dominant  inherited  genetic  disease 
characterized  by  compensatory  LV  hypertrophy  mainly  due  to  sarcomere  dysfunction. 
Prevalence of the disorder in the general population is estimated to be 0.2% [1]. A subset of 
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patients with HCM has hypertrophic obstructive cardiomyopathy (HOCM), in which systolic 
septal  bulging  into  the  LVOT,  malposition  of  the  anterior  papillary  muscle,  with  enlarged 
posterior mitral  leaflet and hyperdynamic LV contraction and drag forces, through a Venturi 
effect,  provoke  systolic  anterior  motion  of  the  anterior  leaflet  of  the  mitral  valve  (SAM), 
contributing to the creation of the LVOT gradient. The degree of LVOT obstruction is generally 
variable, with only a minority of patients presenting significant LVOT gradient at rest. In the 
majority of HOCM the LVOT obstruction is only "latent" or "provocable" by stimuli such as 
exercise,  drugs  (amyle  nitrate),  Valsalva  maneuver  and  postextra-  systolic  potentiation  [2]. 
Resting  (basal)  obstruction  in  HOCM  is  an  independent  predictor  of  adverse  clinical 
consequences  such  as  progressive  heart  failure  and  cardiovascular  death,  including  sudden 
cardiac  death  (SCD)  [3,4].                                  
Overview  of  the  treatment  in  HOCM                                 
Medical therapy is at least partially effective in the majority of HOCM patients [5] and consists 
of  beta-blockers,  calcium  channel  blockers  and  disopyramide,  the  later  being  of  particular 
benefit in patients with associated atrial fibrillation due to its atrial antiarrhythmic properties.
In severely symptomatic HOCM patients despite optimal medical treatment and with significant 
resting or provocable LVOT obstruction (with gradient ≥30 mm Hg at rest or ≥50 mm Hg during 
exercise)  non-pharmacologic  treatment  is  indicated  [5].  Invasive therapies  should be able  to 
alleviate  LVOT  obstruction  either  by  increasing  LVOT  systolic  diameter  and/or  by 
reducing/eliminating SAM. Surgical septal myectomy is the gold standard in this respect, being 
able to concomitantly eliminate anomalies of mitral valve apparatus by concomitant mitral valve 
repair.
Surgical myectomy is effective in >90% of patients, with long-term survival similar to that of 
the  general  population  [6]  and  a  potential  association  with  a  reduction  in  SCD  [7].  In 
experienced centres perioperative mortality is <1% and risk of atrioventricular bock (AVB) is 
<3% [8].  The  rate  of  perioperative  mortality  and  major  complications  may be  significantly 
higher in patients with significant co-morbidities, particularly in those over 65 years old [9,10].
Percutaneous alcohol septal ablation (ASA) can achieve significant LVOT gradient reduction 
and symptomatic  benefit  in  approximately  80% of HOCM patients,  with long-term survival 
comparable with surgical myectomy. ASA-related mortality is 1.5-3% and there is a 10-20% 
risk of chronic AVB [11-13]. Moreover, 9 to 13% of patients require a second procedure and 3-
5%  surgical  myectomy  [11,12].  There  is  also  ongoing  concern  about  SCD/ventricular 
arrhythmia  due  to  ASA-induced  septal  myocardial  necrosis,  which  might  in  the  long  term 
behave as an arrhythmogenic substrate. Although to date most of the reports suggest that ASA is 
not  associated  with  an  increase  in  SCD/ventricular  arrhythmia  [14],  it  is  worrisome  that 
successful LVOT gradient reduction by ASA does not reduce the risk for malignant arrhythmias 
in  high-risk  HOCM  patients  [15,16].                               
Percutaneous  radiofrequency  (RF)  septal  ablation  is  a  recently  introduced  method  that  can 
relieve LVOT gradient through RF-induced necrosis in the basal septum. It has the theoretical 
advantages that it is not dependent on coronary artery anatomy and can precisely identify His 
bundle and its branches and therefore avoid their damage. However, recently published small 
series showed persistent significant LVOT gradient in more than 20% of the HOCM patients, 
with significant perioperative mortality and life-threatening complications (including malignant 
ventricular arrhythmia), and a >20% rate of AVB [17,18]. Moreover, for the moment data on 
long-term risk  for  SCD/ventricular  arrhythmia  are  lacking.                             
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DDD  pacing  in  HOCM                                     
Surgical myectomy and ASA can carry unacceptable risks and/or are not suitable in selected 
subsets of patients with HOCM and severe LV obstruction. Dual-chamber (DDD) pacing with a 
short  atrioventricular  delay,  a  widely  available  alternative,  initially  raised  interest  for  the 
treatment of LVOT obstruction. Two main mechanisms, systolic and diastolic, are known to be 
involved in reducing LV gradient with DDD-right ventricular apex (RVA) pacing. The systolic 
mechanism relies on the paradoxical motion of the interventricular septum induced by altered 
LV depolarization, which delays contraction of the basal interventricular septum and therefore 
increases the systolic dimension of the LVOT [19] with secondary reduction in systolic anterior 
motion of the mitral valve. The diastolic mechanism relies on the improved LV filling due to 
optimized timing of atrial systole [20]. Observational studies and a non-blinded randomized trial 
have suggested that DDD pacing produces gradient reduction, with symptomatic and functional 
benefit  [21-23].  Subsequent  single  and  multicentre  randomized  trials  demonstrated  average 
LVOT gradient reductions of only 50 percent and no improvement in exercise capacity [24-26], 
suggesting a placebo effect for the symptomatic improvement [24,27]. One possible explanation 
for  this  limited  response  could  be  that  the  change in  motion  of  the  interventricular  septum 
induced by RVA pacing is too small to significantly reduce the LVOT gradient, because many 
HOCM patients have a very rapid AV conduction [28] and/or the RVA sites are at a distance 
away from the LV apex [29]. Moreover, recent long-term follow-up data suggests that DDD 
pacing  in  HOCM patients  might  have  a  deleterious  effect  on  survival  and  heart  failure  by 
comparison with conservative management [30]. Based on some of these data current guidelines 
assign a class IIb indication for DDD pacing in HOCM patients without a bradycardia indication 
[5,31].
The case of atrial synchronous LV or biventricular pacing in HOCM                                
A small number of case reports showed that atrial synchronous LV or biventricular pacing (biV) 
might further reduce the LV pressure gradient and improve symptoms in HOCM, initially in 
patients  with  intraventricular  conduction  delay  [32].  Later  on,  LV/biV  pacing  showed  a 
significant  LVOT  gradient  reduction  superior  to  RVA  pacing  in  HOCM  patients  without 
intraventricular conduction delay [29,33-35]. Recently, published data from three small studies 
suggest  that  LV/biV pacing  might  be  efficient  for  LVOT gradient  reduction  and  symptom 
improvement in a large proportion of HOCM patients not suitable for myectomy or ASA (Table 
1) [36-39].
Table 1
Mechanisms of LVOT gradient reduction with LV/biV pacing                             
In contrast to RVA pacing, LV/biV pacing might be able to induce a supplementary reduction in 
LVOT gradient by an alteration in the contraction of a larger area of the LV. Alternatively, the 
reversed  LV  depolarization  sequence  [35]  caused  by  pre-excitation  of  the  LV 
posterolateral/lateral  wall  during  LV/biV  pacing  may  activate  the  longitudinally  oriented 
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epicardial fibres earlier, thereby advancing lateral wall longitudinal displacement with regard to 
interventricular septal longitudinal displacement [36] and potentially even slightly stretching the 
latter.  This  will  change the pre-ejection  shape and diameter  of the LVOT and mitral  valve, 
which,  together  with  the  induced  reduction  in  septal  systolic  displacement,  can  reduce  the 
intraventricular gradient. Support for the latter hypothesis comes from a case report showing that 
DDD RVA epicardial pacing for complete AV block after septal myectomy induced SAM and 
LVOT gradient, while LV lateral wall pacing completely abolished it [39]. SAM disappearance 
was also observed in the majority of HOCM patients after 6 months of LV/biV pacing [37].
LV/biV  implant  procedure  outcome                               
Recently published small studies with LV/biV pacing in HOCM showed an acute success rate of 
transvenous LV lead implantation ranging from 75-80% [36,37] to 100% [39] compared to the 
94.4% CRT implantation rate in patients with LV systolic dysfunction [40] or 100% in patients 
with  dilated  (end-stage)  phase  of  hypertrophic  cardiomyopathy  [41].  Causes  of  LV  lead 
implantation failure were: impossibility to cannulate coronary sinus (CS) ostium [36,37], intense 
phrenic  nerve  stimulation  despite  LV  repositioning  [37]  and  CS  dissection  [37].  Possible 
explanations  are  the  smaller  and/or  tortuous  coronary  sinus  and  its  ventricular  branches  in 
concentrically  hypertrophied  non-dilated  LV of  HOCM patients  (Figure  1),  as  well  as  the 
limited experience of the operators in this population and/or lack of specifically adapted LV 
leads. It is possible that newer generation LV leads, with smaller diameter (around 4F for bipolar 
leads) and better  trackability could help to increase success rates. A low rate of LV lead or 
device-related complications have been described on long–term follow-up, although in one of 
the three small pilot studies the LV lead was extracted in three of eight cases (one due to device 
infection)  [37].  Additionally,  in  a  very  recent  retrospective  analysis  of  a  single-centre  ICD 
registry  in  patients  with  HCM,  22%  of  the  CRT-D  subgroup  showed  LV  lead-related 
complications [42].
Figure 1: A: RAO projection showing the occlusive venography in a hypertrophic obstructive cardiomyopathy 
patient; note the extreme tortuousity as well as the reduced diameter of the target coronary sinus ventricular branch.  
B:  The  same  RAO  projection  showing  the  final  lead  position  of  the  leads  (a  4F  bipolar  lead  was  used).
Symptoms  and  functional  capacity                                       
Small long-term pilot studies have shown improvements of at least one NYHA functional class 
with LV/biV pacing [36] even in less symptomatic HOCM patients [37], with a marked and 
progressive increase in quality of life [36,38] and functional  capacity evaluated by 6-minute 
walk test (6MWT) [36,37], treadmill exercise test [38] or peak oxygen consumption (VO2 peak) 
[37] (Table 1). In one of the studies a non-uniform response to LV/biV pacing was observed: 
two out of eight patients were symptomatic non-responders, three responded to biV pacing and 
three  to  RVA  pacing  [38].  However,  in  this  study  the  optimal  pacing  configuration  was 
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established by the maximum symptomatic benefit observed after a serial crossover comparison 
between no active pacing vs. RVA pacing or biV pacing. Additionally, in non-responders mean 
LVOT gradient at rest was less significant (around 25 mm Hg) and in three out of eight patients 
previous septal reduction therapies failed (ASA in two patients and myectomy in another one) 
[38]. Other studies decided the optimal pacing configuration to be the one that acutely induces 
the  maximum  LVOT  gradient  reduction  [36,37],  possibly  explaining  their  higher  rate  of 
responders. Overall LV/biV seems to favourably compare with studies on DDD RVA pacing in 
HOCM,  which  failed  to  show  significant  improvement  in  functional  capacity  [24-26].
LVOT  obstruction                                              
In the overwhelming majority of HOCM patients LV/biV pacing is acutely more effective for 
gradient reduction than standard RVA pacing: eight out of nine in one study [36] and all nine 
patients in another [37]. Even when optimal pacing configuration was selected by symptomatic 
improvement,  clinical  non-responders  and patients  selected  for RVA pacing still  achieved a 
greater reduction in LVOT gradient with biV pacing. [38] (Table 1). Moreover, LVOT gradient 
progressively decreased during follow-up, with a mean LVOT gradient at rest below 30 mm Hg 
at medium term [36,37], reaching almost non-significant  levels at  three years [37].  Acutely, 
SAM  is  still  present  (although  with  a  significantly  reduced  contact  time;  unpublished 
observations,  Dr.  Vidal)  [36].  Long-term,  LV/biV  pacing  is  associated  with  a  continuous 
reduction of SAM [36] or even complete disappearance in the majority of HOCM patients [37] 
(Figure 2).  This  is  concordant  with a continuous and significant  reduction in  the degree of 
mitral  regurgitation  [36].  Interestingly,  one  of  the  studies  showed  that  the  optimal 
atrioventricular  and  interventricular  intervals  for  maximum LVOT gradient  reduction  at  six 
months follow-up were different than those at baseline for more than 50% of the patients [37].
Figure 2: Upper panels show Mmode scans across the left ventricle and the mitral valve before (preBiv) and after  
atrial  synchronous biventricular  pacing (postBiv):  arrows indicate systolic anterior motion (SAM) of the mitral 
valve, which touches the septum preBiv and does not contact it postBiv. These changes in the degree of SAM are  
concomitantly seen with a significant decrease of LVOT gradient (from 76 to 48 mmHg). In this patient, atrial  
synchronous right ventricular apical pacing did not change the left ventricular outflow tract gradient.
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LV  reverse  remodeling                                           
In contrast to studies with DDD RVA pacing, LV/biV pacing showed that the reduction in LVOT 
gradient induced a progressive and significant reduction in LV mass (reverse remodelling) [36]. 
The thinning seems to be significant only for the interventricular septum [36,37], although there 
was  also  a  trend  in  the  LV posterior  wall  [36].  This  is  not  surprising,  considering  that  LV 
hypertrophy  in  young  patients  with  HOCM  is  at  least  partially  also  secondary  to  LVOT 
obstruction [43] and that septal  reduction therapies  induce LV reverse remodelling,  with wall 
thinning in areas distant from the interventricular septum [44,45].                              
LV/biV pacing in HOCM and SCD / ventricular arrhythmia                                   
During long term LV/biV pacing in HOCM there was no SCD/syncope in patients with CRT-P 
[36-38]. In the group of CRT-D patients, only one experienced appropriate ICD therapies [37]. 
Although the pooled number of studies with LV/biV pacing in HOCM is small, it is tempting to 
speculate  that  this  therapy,  which  is  able  to  reduce  LVOT  gradient  and  induce  LV  reverse 
remodelling without creating a septal scar, does not increase the SCD/VA risk. Data from CRT 
studies in patients with LV systolic dysfunction also demonstrate that the risk of SCD/VA is  
reduced in the presence of significant LV reverse remodeling [46, 47].                                
Limitations  
The small number of patients included in studies with LV/biV pacing in HOCM as well as the fact 
that all  of them are observational and uncontrolled (i.e.,  a placebo effect  of pacing cannot be 
excluded)  requires  caution  in  interpreting  the  results.  However,  the  differences  observed  in 
comparison with standard DDD RVA pacing warrants further research. Considering the relatively 
large number of HOCM patients submitted to cardioverter-defibrillator implantation for primary 
or  secondary  prevention,  data  for  such  analysis  should  be  readily  available.  
Conclusion  
In selected patients with HOCM, LV/biV pacing is feasible and usually the best configuration for 
gradient  reduction.  Overall,  LV/biV  pacing  in  patients  with  HOCM  significantly  and 
progressively improves functional capacity and quality of life.  It  may also induce LV reverse 
remodelling.
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